141 related articles for article (PubMed ID: 38513740)
1. Sensitization of cancer cells to paclitaxel-induced apoptosis by canagliflozin.
Huang H; Kung FL; Huang YW; Hsu CC; Guh JH; Hsu LC
Biochem Pharmacol; 2024 May; 223():116140. PubMed ID: 38513740
[TBL] [Abstract][Full Text] [Related]
2. Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway.
Zhou J; Zhu J; Yu SJ; Ma HL; Chen J; Ding XF; Chen G; Liang Y; Zhang Q
Biomed Pharmacother; 2020 Dec; 132():110821. PubMed ID: 33068934
[TBL] [Abstract][Full Text] [Related]
3. Boosting the apoptotic response of high-grade serous ovarian cancers with CCNE1 amplification to paclitaxel in vitro by targeting APC/C and the pro-survival protein MCL-1.
Raab M; Kobayashi NF; Becker S; Kurunci-Csacsko E; Krämer A; Strebhardt K; Sanhaji M
Int J Cancer; 2020 Feb; 146(4):1086-1098. PubMed ID: 31286496
[TBL] [Abstract][Full Text] [Related]
4. Mad2 and BubR1 modulates tumourigenesis and paclitaxel response in MKN45 gastric cancer cells.
Bargiela-Iparraguirre J; Prado-Marchal L; Pajuelo-Lozano N; Jiménez B; Perona R; Sánchez-Pérez I
Cell Cycle; 2014; 13(22):3590-601. PubMed ID: 25483095
[TBL] [Abstract][Full Text] [Related]
5. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
Suga T; Kikuchi O; Kobayashi M; Matsui S; Yokota-Hashimoto H; Wada E; Kohno D; Sasaki T; Takeuchi K; Kakizaki S; Yamada M; Kitamura T
Mol Metab; 2019 Jan; 19():1-12. PubMed ID: 30416006
[TBL] [Abstract][Full Text] [Related]
6. Differentiating the Sodium-Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling.
Sokolov V; Yakovleva T; Chu L; Tang W; Greasley PJ; Johansson S; Peskov K; Helmlinger G; Boulton DW; Penland RC
CPT Pharmacometrics Syst Pharmacol; 2020 Apr; 9(4):222-229. PubMed ID: 32064793
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study.
Sha S; Polidori D; Farrell K; Ghosh A; Natarajan J; Vaccaro N; Pinheiro J; Rothenberg P; Plum-Mörschel L
Diabetes Obes Metab; 2015 Feb; 17(2):188-97. PubMed ID: 25421015
[TBL] [Abstract][Full Text] [Related]
8. Peloruside A, a microtubule-stabilizing agent, induces aneuploidy in ovarian cancer cells.
Chan A; Singh AJ; Northcote PT; Miller JH
Invest New Drugs; 2016 Aug; 34(4):424-38. PubMed ID: 27155614
[TBL] [Abstract][Full Text] [Related]
9. SGLT2 inhibition restrains thyroid cancer growth via G1/S phase transition arrest and apoptosis mediated by DNA damage response signaling pathways.
Wang Y; Yang L; Mao L; Zhang L; Zhu Y; Xu Y; Cheng Y; Sun R; Zhang Y; Ke J; Zhao D
Cancer Cell Int; 2022 Feb; 22(1):74. PubMed ID: 35148777
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness in the inhibition of dapagliflozin and canagliflozin on M-type K
So EC; Liu PY; Wu SN
Eur J Pharmacol; 2020 Jul; 879():173141. PubMed ID: 32353360
[TBL] [Abstract][Full Text] [Related]
11. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
Chu C; Lu YP; Yin L; Hocher B
Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
Zaccardi F; Webb DR; Htike ZZ; Youssef D; Khunti K; Davies MJ
Diabetes Obes Metab; 2016 Aug; 18(8):783-94. PubMed ID: 27059700
[TBL] [Abstract][Full Text] [Related]
13. Antagonizing the spindle assembly checkpoint silencing enhances paclitaxel and Navitoclax-mediated apoptosis with distinct mechanistic.
Henriques AC; Silva PMA; Sarmento B; Bousbaa H
Sci Rep; 2021 Feb; 11(1):4139. PubMed ID: 33603057
[TBL] [Abstract][Full Text] [Related]
14. Suppression of spindly delays mitotic exit and exacerbates cell death response of cancer cells treated with low doses of paclitaxel.
Silva PM; Ribeiro N; Lima RT; Andrade C; Diogo V; Teixeira J; Florindo C; Tavares Á; Vasconcelos MH; Bousbaa H
Cancer Lett; 2017 May; 394():33-42. PubMed ID: 28249757
[TBL] [Abstract][Full Text] [Related]
15. Safety assessment of the SGLT2 inhibitors empagliflozin, dapagliflozin and canagliflozin during pregnancy: An ex vivo human placenta perfusion and in vitro study.
Kuoni S; Steiner R; Saleh L; Lehmann R; Ochsenbein-Kölble N; Simões-Wüst AP
Biomed Pharmacother; 2024 Feb; 171():116177. PubMed ID: 38262151
[TBL] [Abstract][Full Text] [Related]
16. Targeting mitotic exit with hyperthermia or APC/C inhibition to increase paclitaxel efficacy.
Giovinazzi S; Bellapu D; Morozov VM; Ishov AM
Cell Cycle; 2013 Aug; 12(16):2598-607. PubMed ID: 23907120
[TBL] [Abstract][Full Text] [Related]
17. Mechanistic evaluation of the effect of sodium-dependent glucose transporter 2 inhibitors on delayed glucose absorption in patients with type 2 diabetes mellitus using a quantitative systems pharmacology model of human systemic glucose dynamics.
Mori-Anai K; Tashima Y; Nakada T; Nakamaru Y; Takahata T; Saito R
Biopharm Drug Dispos; 2020 Nov; 41(8-9):352-366. PubMed ID: 33085977
[TBL] [Abstract][Full Text] [Related]
18. Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake.
Kaji K; Nishimura N; Seki K; Sato S; Saikawa S; Nakanishi K; Furukawa M; Kawaratani H; Kitade M; Moriya K; Namisaki T; Yoshiji H
Int J Cancer; 2018 Apr; 142(8):1712-1722. PubMed ID: 29205334
[TBL] [Abstract][Full Text] [Related]
19. Exploring the Role of Sodium-Glucose Cotransporter as a New Target for Cancer Therapy.
Bardaweel S; Issa A
J Pharm Pharm Sci; 2022; 25():253-265. PubMed ID: 35977549
[TBL] [Abstract][Full Text] [Related]
20. Distinctive effects of SGLT2 inhibitors on angiogenesis in zebrafish embryos.
Huttunen R; Sainio A; Hjelt A; Haapanen-Saaristo AM; Määttä J; Rummukainen P; Paatero I; Järveläinen H
Biomed Pharmacother; 2022 Dec; 156():113882. PubMed ID: 36265308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
